BLTE רווח נקי למניה (EPS TTM) Belite Bio

Belite Bio, Inc (BLTE) is developing ophthalmological innovations while adhering to basic eco-standards for office consumption. The fundamental TTM net income per share provided by the GURU.Markets platform reflects price dynamics, while -2.81 shapes the current metric. The brand's high scientific authority is coupled with financial risks stemming from a lack of revenue and dependence on clinical trial outcomes.

To objectively evaluate the issuer, a manager requires the calculation of net income distributed per share over the last 12 months, which allows for the elimination of the impact of the total shares outstanding on the final result. An analysis of the fundamental net income per share TTM demonstrates the real operational efficiency of Belite Bio, Inc. (BLTE), which currently depends directly on the successful commercialization of therapies for retinal diseases.